Research ArticleArticle
Small-Molecule Ligands that Bind the RET Receptor Activate Neuroprotective Signals Independent of but Modulated by Coreceptor GFRα1
Sean Jmaeff, Yulia Sidorova, Hayley Lippiatt, Pablo F. Barcelona, Hinyu Nedev, Lucia M. Saragovi, Mark A. Hancock, Mart Saarma and H. Uri Saragovi
Molecular Pharmacology July 2020, 98 (1) 1-12; DOI: https://doi.org/10.1124/mol.119.118950
Sean Jmaeff
Lady Davis Institute - Jewish General Hospital (S.J., H.L., P.F.B., H.N., L.M.S., H.U.S.), Pharmacology and Therapeutics (S.J., H.U.S.), and SPR-MS Facility (M.H.), McGill University, Montreal, Canada; and Institute of Biotechnology, HiLIFE, University of Helsinki, Helsinki, Finland (Y.S., M.S.)
Yulia Sidorova
Lady Davis Institute - Jewish General Hospital (S.J., H.L., P.F.B., H.N., L.M.S., H.U.S.), Pharmacology and Therapeutics (S.J., H.U.S.), and SPR-MS Facility (M.H.), McGill University, Montreal, Canada; and Institute of Biotechnology, HiLIFE, University of Helsinki, Helsinki, Finland (Y.S., M.S.)
Hayley Lippiatt
Lady Davis Institute - Jewish General Hospital (S.J., H.L., P.F.B., H.N., L.M.S., H.U.S.), Pharmacology and Therapeutics (S.J., H.U.S.), and SPR-MS Facility (M.H.), McGill University, Montreal, Canada; and Institute of Biotechnology, HiLIFE, University of Helsinki, Helsinki, Finland (Y.S., M.S.)
Pablo F. Barcelona
Lady Davis Institute - Jewish General Hospital (S.J., H.L., P.F.B., H.N., L.M.S., H.U.S.), Pharmacology and Therapeutics (S.J., H.U.S.), and SPR-MS Facility (M.H.), McGill University, Montreal, Canada; and Institute of Biotechnology, HiLIFE, University of Helsinki, Helsinki, Finland (Y.S., M.S.)
Hinyu Nedev
Lady Davis Institute - Jewish General Hospital (S.J., H.L., P.F.B., H.N., L.M.S., H.U.S.), Pharmacology and Therapeutics (S.J., H.U.S.), and SPR-MS Facility (M.H.), McGill University, Montreal, Canada; and Institute of Biotechnology, HiLIFE, University of Helsinki, Helsinki, Finland (Y.S., M.S.)
Lucia M. Saragovi
Lady Davis Institute - Jewish General Hospital (S.J., H.L., P.F.B., H.N., L.M.S., H.U.S.), Pharmacology and Therapeutics (S.J., H.U.S.), and SPR-MS Facility (M.H.), McGill University, Montreal, Canada; and Institute of Biotechnology, HiLIFE, University of Helsinki, Helsinki, Finland (Y.S., M.S.)
Mark A. Hancock
Lady Davis Institute - Jewish General Hospital (S.J., H.L., P.F.B., H.N., L.M.S., H.U.S.), Pharmacology and Therapeutics (S.J., H.U.S.), and SPR-MS Facility (M.H.), McGill University, Montreal, Canada; and Institute of Biotechnology, HiLIFE, University of Helsinki, Helsinki, Finland (Y.S., M.S.)
Mart Saarma
Lady Davis Institute - Jewish General Hospital (S.J., H.L., P.F.B., H.N., L.M.S., H.U.S.), Pharmacology and Therapeutics (S.J., H.U.S.), and SPR-MS Facility (M.H.), McGill University, Montreal, Canada; and Institute of Biotechnology, HiLIFE, University of Helsinki, Helsinki, Finland (Y.S., M.S.)
H. Uri Saragovi
Lady Davis Institute - Jewish General Hospital (S.J., H.L., P.F.B., H.N., L.M.S., H.U.S.), Pharmacology and Therapeutics (S.J., H.U.S.), and SPR-MS Facility (M.H.), McGill University, Montreal, Canada; and Institute of Biotechnology, HiLIFE, University of Helsinki, Helsinki, Finland (Y.S., M.S.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
Validation of RET Receptor as a Druggable Target
Sean Jmaeff, Yulia Sidorova, Hayley Lippiatt, Pablo F. Barcelona, Hinyu Nedev, Lucia M. Saragovi, Mark A. Hancock, Mart Saarma and H. Uri Saragovi
Molecular Pharmacology July 1, 2020, 98 (1) 1-12; DOI: https://doi.org/10.1124/mol.119.118950
Research ArticleArticle
Validation of RET Receptor as a Druggable Target
Sean Jmaeff, Yulia Sidorova, Hayley Lippiatt, Pablo F. Barcelona, Hinyu Nedev, Lucia M. Saragovi, Mark A. Hancock, Mart Saarma and H. Uri Saragovi
Molecular Pharmacology July 1, 2020, 98 (1) 1-12; DOI: https://doi.org/10.1124/mol.119.118950
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement